There is growing interest in the potential therapeutic applications of Annexin V in cancer. For instance, targeted delivery of Annexin V to cancer cells could be used to enhance the efficacy of apoptosis-inducing drugs. Additionally, because some cancer cells express higher levels of phosphatidylserine on their surface, Annexin V-conjugated drugs could selectively target these cells, sparing normal cells and reducing side effects.
